Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03854110 |
| Title | A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine (MIROC-1) |
| Acronym | MIROC-1 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Persevere Therapeutics Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Rush University Medical Center | RECRUITING | Chicago | Illinois | 60607 | United States | Details |
| University of Kansas Cancer Center | RECRUITING | Fairway | Kansas | 66205 | United States | Details |
| Beth Israel Deaconess Medical Center | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| Abramson Cancer Center at the University of Pennsylvania | RECRUITING | Phildelphia | Pennsylvania | 19104 | United States | Details |